tag small-cell-lung-cancer 
Fierce Pharma
SEPTEMBER 22, 2023
Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break. Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break.
pharmaphorum
JULY 25, 2022
The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer.
PM360
APRIL 7, 2023
The shift toward longer, more adequate timeframes to establish proof of concept can be as long as three to four years, 1 given the complex requirements for developing and launching specialty drugs and cell and gene therapies (CGTs) for individuals with complex conditions or rare or orphan diseases. References: 1. Carroll, J.P.
Expert insights. Personalized for you.
302 
Let's personalize your content